Performance of Anti–Cyclic Citrullinated Peptide Assays Differs in Subjects at Increased Risk of Rheumatoid Arthritis and Subjects With Established Disease

Abstract

Anti-CCP assays differ to an extent that may be meaningful for diagnosing RA in patients with inflammatory arthritis and evaluating the natural history of RA development in subjects at risk of RA. The mechanisms underlying these differences in test performance need further investigation.